The clearance allows the bone void filler to be used with NuVasive’s procedurally integrated thoracolumbar interbody portfolio, NuVasive stated in a news release. Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler designed to enable bone formation without added cells or growth factors.
This indication makes the bone void filler the first synthetic biologic cleared for use in interbody fusions of the thoracolumbar spine. It’s also supported by a level 1 trial for use in posterolateral spinal fusions.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
